Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial

Table 1 Patient demographics and surgical results

	ZA group (n = 27)	Control group (n = 27)
Age (years), mean (SD)	60.1 (11.7)	59.4 (13.3)
Sex, female:male	15:12	14:13
BMI (kg/m²), mean (SD)	26 (4)	25 (5)
Operation time (minutes), mean (SD)^a	118 (27)	103 (17)
Blood loss (mL), mean (SD)	502 (312)	387 (162)
Diagnosis (OA/AVN)	16/11	17/10

BMI body mass index, SD standard deviation, ZA zoledronic acid, OA osteoarthritis, AVN avascular necrosis
^astatistically significant difference between the ZA and control groups (P < 0.05)

ISSN: 1471-2474